Last reviewed · How we verify
Lansoprazole and naproxen and aspirin
Lansoprazole and naproxen and aspirin is a Proton pump inhibitor + NSAID combination Small molecule drug developed by Takeda. It is currently in Phase 3 development for Reduction of NSAID-induced gastric ulcers in patients requiring chronic NSAID therapy for pain and inflammation.
This combination product reduces gastric acid secretion via lansoprazole while providing anti-inflammatory and analgesic effects through naproxen and aspirin, with the proton pump inhibitor protecting against NSAID-induced gastrointestinal injury.
This combination product reduces gastric acid secretion via lansoprazole while providing anti-inflammatory and analgesic effects through naproxen and aspirin, with the proton pump inhibitor protecting against NSAID-induced gastrointestinal injury. Used for Reduction of NSAID-induced gastric ulcers in patients requiring chronic NSAID therapy for pain and inflammation.
At a glance
| Generic name | Lansoprazole and naproxen and aspirin |
|---|---|
| Sponsor | Takeda |
| Drug class | Proton pump inhibitor + NSAID combination |
| Target | H+/K+-ATPase (lansoprazole); COX-1 and COX-2 (naproxen and aspirin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Lansoprazole is a proton pump inhibitor that suppresses gastric acid production by blocking H+/K+-ATPase in parietal cells. Naproxen and aspirin are nonsteroidal anti-inflammatory drugs that inhibit cyclooxygenase (COX) enzymes to reduce inflammation and pain. The combination is designed to provide NSAID efficacy while the lansoprazole component mitigates the gastrointestinal toxicity associated with chronic NSAID use.
Approved indications
- Reduction of NSAID-induced gastric ulcers in patients requiring chronic NSAID therapy for pain and inflammation
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
- Dyspepsia
Key clinical trials
- A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lansoprazole and naproxen and aspirin CI brief — competitive landscape report
- Lansoprazole and naproxen and aspirin updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about Lansoprazole and naproxen and aspirin
What is Lansoprazole and naproxen and aspirin?
How does Lansoprazole and naproxen and aspirin work?
What is Lansoprazole and naproxen and aspirin used for?
Who makes Lansoprazole and naproxen and aspirin?
What drug class is Lansoprazole and naproxen and aspirin in?
What development phase is Lansoprazole and naproxen and aspirin in?
What are the side effects of Lansoprazole and naproxen and aspirin?
What does Lansoprazole and naproxen and aspirin target?
Related
- Drug class: All Proton pump inhibitor + NSAID combination drugs
- Target: All drugs targeting H+/K+-ATPase (lansoprazole); COX-1 and COX-2 (naproxen and aspirin)
- Manufacturer: Takeda — full pipeline
- Therapeutic area: All drugs in Gastroenterology / Rheumatology
- Indication: Drugs for Reduction of NSAID-induced gastric ulcers in patients requiring chronic NSAID therapy for pain and inflammation
- Compare: Lansoprazole and naproxen and aspirin vs similar drugs
- Pricing: Lansoprazole and naproxen and aspirin cost, discount & access